TABLE 1

Characteristics of patients enrolled in this study and results for each test

Patient characteristic or testaMean ± SD (no. of patients or as indicated), no. (%) of patients, or as indicatedP valuec
CPA group (n = 50)bRespiratory disease control group (n = 65)
Characteristics
    Age (yrs)68.4 ± 11.664.6 ± 11.10.0808
    No. of patients male/female40/1037/280.01
    Prior pulmonary tuberculosis infection10 (20)3 (4.6)0.0042
    COPD8 (16)3 (4.6)0.0551
    Non-tuberculosis Mycobacterium infection12 (24)9 (13.8)0.2236
    Interstitial pneumonia15 (30)25 (38.5)0.4303
    Prior lung surgery12 (24)4 (6.2)0.0124
    Lung cancer3 (6)3 (4.6)0.9999
    Bacterial infection (pneumonia, lung abscess)08 (13.4)0.0094
    Hematological malignancy05 (7.7)0.0676
    Diabetes mellitus12 (24)13 (20)0.6527
    Corticosteroid usage10 (20)20 (30.8)0.2074
    Immunosuppressant usage4 (8)10 (15.4)0.2645
Tests (result)
    Serum AspLFD (positive)31 (62)21 (32.3)0.0024
    BAL fluid AspLFD (positive)22 (64.7)20 (30.8)0.1733
    Serum GM (index)1.49 ± 2.170.86 ± 0.980.0407
    BAL fluid GM (index)3.71 ± 4.490.74 ± 1.96<0.0001
    Aspergillus precipitating antibody (positive)35 (70)0 (0)<0.0001
    Serum BDG (pg/ml)57.6 ± 147.7111.4 ± 9.30.0132
    Fungal culture
        A. fumigatus28 (56)
        A. terreus4 (8)
        A. niger2 (4)
        A. nidulans2 (4)
        Aspergillus spp. (unidentifiable)1 (2)
        Negative13 (26)
  • a CCPA, chronic cavitary pulmonary aspergillosis; SAIA, subacute invasive aspergillosis; SPA, simple pulmonary aspergilloma; COPD, chronic obstructive pulmonary disease; AspLFD, Aspergillus-specific lateral-flow device; BAL, bronchoalveolar lavage: GM, galactomannan; BDG, β-d-glucan.

  • b Categories of CPA and proportions of patients were as follows: CCPA, 32 (64%); SAIA, 10 (20%); and SPA, 8 (16%).

  • c A P value of <0.05 (Fisher’s exact test or unpaired t test) was considered significant. Values in boldface are significant.